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i.org/1sarcoidosis (CS). Because of the limited sensitivity of endomyocardial biopsy (EMB),
conﬁrmation of sarcoidosis often has to be acquired from extracardiac biopsies. We set out
to review our experience of F-18-ﬂuorodeoxyglucose positron emission tomography
(F-18-FDG PET) in guiding extracardiac tissue biopsies in suspected CS. We included in
this work 68 consecutive patients with proved CS who had undergone cardiac F-18-FDG
PET with (n [ 57) or without whole-body imaging as part of initial diagnostic evalua-
tion. Their hospital charts, imaging studies, and diagnostic biopsies were reviewed
in retrospect. Whole-body PET images showed extracardiac foci of abnormally high
F-18-FDG uptake in 39 of 57 patients, of whom 38 had involvement of mediastinal lymph
nodes (MLN). Parallel F-18-FDG uptake was found in other lymph nodes (n [ 10), lungs
(n[ 9), liver (n[ 3), spleen (n[ 2), and thyroid gland (n[ 1). Adding the mediastinal
ﬁndings at cardiac PET without whole-body imaging, abnormal F-18-FDG uptake in MLN
was found in totally 43 of the 68 patients with CS (63%). Histology of systemic sarcoidosis
was known at presentation of cardiac symptoms in 8 patients. Of the 60 patients with
missing histology, 24 patients underwent mediastinoscopy for sampling of PET-positive
MLN, most often (n [ 20) after nondiagnostic EMB; microscopy revealed diagnostic
noncaseating granulomatous inﬂammation in 24 of the 24 cases (sensitivity 100%). In the
remaining 36 patients, sarcoidosis histology was conﬁrmed by EMB (n[ 30), by biopsy of
lungs (n [ 2) or peripheral lymph nodes (n [ 2), or at autopsy (n [ 1) or post-
transplantation (n [ 1). In conclusion, MLN accumulate F-18-FDG at PET in most
patients with CS and provide a highly productive source for diagnostic biopsies either
primarily or subsequent to nondiagnostic EMB.  2015 Elsevier Inc. All rights reserved.
(Am J Cardiol 2015;116:1581e1585)Cardiac sarcoidosis (CS) presents to the cardiology
services as an isolated heart condition much more
commonly than as one manifestation of a known or clini-
cally evident systemic sarcoidosis.1,2 Its main forms of
presentation are atrioventricular conduction block, ventric-
ular tachyarrhythmias, and heart failure, either alone or in
various combinations.1e3 Distinguishing CS from more
common myocardial conditions, ischemic or nonischemic, isardiology, Heart and Lung Center and bDepartment of
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The only absolute diagnosis of CS comes from ﬁnding
typical granulomatous myocarditis in a sample of myocar-
dium without other explanation. However, because of the
patchy distribution of sarcoid granulomas, endomyocardial
biopsy (EMB) more often misses than hits areas diagnostic
of CS resulting in a sensitivity no better than 19% to
32%.4e6 CS can be diagnosed with less but clinically suf-
ﬁcient certainty also if the histology is proved in an
extracardiac tissue sample and clinical manifestations and
ﬁndings at cardiac gadolinium-enhanced magnetic reso-
nance imaging (Gd-MRI) or F-18-ﬂuorodeoxyglucose
positron emission tomography (F-18-FDG PET) are
compatible with myocardial involvement.6 Since the ﬁrst
published cardiac F-18-FDG PET images in CS,7 with
focally increased myocardial glucose uptake signaling
inﬂammatory activity, PET has gained wide use in the initial
diagnosis, assessment of disease activity, and monitoring of
treatment response in CS.8e10 Moreover, whole-body PET
can uncover hidden inﬂammatory foci in extracardiac
organs,11 thus suggesting targets for diagnostic tissue
biopsies. We set out to review our nationwide CS registry2
for details of the use of F-18-FDG PET in the detection ofwww.ajconline.org




















Figure 1. Summary of the diagnostic strategy in suspicion of CS during
the study period. EcFDG ¼ abnormal extracardiac F-18-FDG uptake;
LGE ¼ late gadolinium enhancement; MyocFDG ¼ abnormal myocardial
F-18-FDG uptake.
1582 The American Journal of Cardiology (www.ajconline.org)CS. In the present work, we focus on extracardiac PET
ﬁndings and show their utility in the diagnosis of CS.
Methods
The registry of Myocardial Inﬂammatory Diseases in
Finland has collected all patients diagnosed in our country
with clinically manifest CS since the turn of 1990s.2 The
criteria of CS required for inclusion in the registry have been
detailed in our earlier reports.2,5,12 In brief, either myocar-
dial or extracardiac histology of noncaseating granuloma-
tous inﬂammation has been mandatory in addition to clinical
manifestations and ﬁndings at cardiac imaging compatible
with CS. From this database, we identiﬁed 72 patients with
CS who had undergone F-18-FDG PET from 2005 to early
2013 as part of their diagnostic assessment after admission.
Of them, 4 patients were excluded because of technically
inadequate PET studies. The remaining 68 patients consti-
tute the present study population. Their hospital charts were
scrutinized in retrospect for demographics, cardiac signs and
symptoms, laboratory tests, imaging studies, and diagnostic
biopsies, and the data pertinent to the present work were
collected for analysis. The study was performed according
to the principles of the Declaration of Helsinki. The Ethics
Committee for the Department of Medicine, Helsinki Uni-
versity Central Hospital, approved the study protocol, and
the Myocardial Inﬂammatory Diseases in Finland registry
study has been approved by the national ethical review
board (STM/1219/2009). A proportion of the CS population
(25 of the 68 patients) has been reported earlier.5
During the period covered by our work, patients pre-
senting with etiologically unknown high-grade atrioven-
tricular conduction disturbance, ventricular
tachyarrhythmia, or heart failure were initially examined
clinically and with routine laboratory tests, chest x-rays, and
echocardiography. Once ischemic heart disease had been
excluded, either clinically or at coronary angiography, pa-
tients usually underwent cardiac Gd-MRI unless it was
contraindicated. If MRI was suggestive of myocardial
inﬂammation by showing Gd late enhancement with or
without edema or abnormal LV wall thinning or thick-
ening,13 a right or left ventricular EMB was done aiming
at the site of myocardial abnormalities identiﬁed in
MRI. Cardiac F-18-FDG PET, usually complemented withwhole-body image acquisition, was done (1) if MRI was
contraindicated, (2) if the results of MRI were nonrevealing
but suspicion of CS persisted, or (3) if the post-MRI
EMB was nondiagnostic. If PET showed focally increased
F-18-FDG uptake in the myocardium, EMB was again
the next procedure. Extracardiac tissue biopsy was done,
provided there was F-18-FDG accumulation outside the
heart if (1) there was no abnormal myocardial F-18-FDG
accumulation or (2) the post-PET EMB was negative.
Figure 1 illustrates this diagnostic strategy.
Most F-18-FDG PET studies (58 of 68) were done at the
Department of Nuclear Medicine, Helsinki University
Central Hospital. The patients fasted for at least 12 hours
before the examination, and blood glucose level had to be
<7.0 mmol/L before the study. After an intravenous injec-
tion of F-18-FDG (303  57 MBq), the uptake phase lasted
at least 60 minutes. PET images were acquired with a Phi-
lips Gemini PET/computed tomographic (CT) scanner. For
the whole-body images, scanning was performed from the
proximal femoral region to the head. Cardiac image acqui-
sition was done thereafter. Within 1 week from the PET/CT
scan, a Tc-99m-tetrofosmin myocardial perfusion imaging
at rest was performed. The details of these imaging methods
have been described previously.5,12 Ten patients underwent
PET in 3 other Finnish university hospitals according to
their local routines. All PET studies, including the ones
done elsewhere, were analyzed by an experienced nuclear
medicine specialist (JS) at the core institution in Helsinki.
Any pathologic uptake of F-18-FDG outside the heart was
located and recorded, including the presence, number, and
size of F-18-FDGepositive mediastinal lymph nodes
(MLN). In cardiac PET, normal myocardial metabolism
was deﬁned as either complete suppression of F-18-FDG
uptake or diffuse uptake without any areas of focally
increased activity (i.e., without F-18-FDG “hot spot”). The
Tc-99m-tetrofosmin myocardial perfusion at rest was
compared with the F-18-FDG uptake in the 17-segment LV
model, and each segment was visually classiﬁed as having
either (1) normal perfusion and normal metabolism,
(2) abnormal perfusion or abnormal metabolism (i.e., “hot
spot”), or (3) abnormal perfusion and abnormal metabolism.
All statistical analyses were performed with the SPSS for
Windows 19.0 Statistics (SPSS, Chicago, Illinois). The data
are presented as mean  SD for continuous variables and as
absolute numbers or percentages for categorical variables,
unless otherwise noted. Normal distribution and homoge-
neity of variance were checked before further analyses.
Between-group comparisons for continuous variables were
made with the Student’s 2-sided t test. Comparisons of
discrete variables between groups were assessed with the
chi-square test or Fisher’s exact test. All statistical tests were
2 tailed, and p <0.05 was regarded as statistically
signiﬁcant.
Results
The CS population comprised 47 women and 21 men
with a mean age of 50  9 years. Their main presenting
cardiac manifestations were, in order of decreasing fre-
quency, complete atrioventricular block (n ¼ 37, 54%),
sustained ventricular tachycardia (n ¼ 18, 26%), congestive
Figure 2. Examples of cardiac (A) and whole-body (B) F-18-FDG PET studies showing “hot” MLN together with foci of activity in the heart and outside the
thoracic cavity.
Table 1
Details of extracardiac localization of F-18-FDG uptake at whole-body PET
in 57 patients with CS
Foci of abnormal extracardiac F-18-FDG uptake n
Mediastinal lymph nodes (only) 21
Mediastinal lymph nodes, lungs 6
Mediastinal and extrathoracic lymph nodes 6
Mediastinal and extrathoracic lymph nodes, lungs 2
Mediastinal and extrahoracic lymph nodes, spleen 1
Mediastinal and extrathoracic lymph nodes, spleen and liver 1
Mediastinal lymph nodes, lungs, liver and thyroid gland 1
Liver (only) 1
No extracardiac uptake 18
CS ¼ cardiac sarcoidosis; F-18-FDG ¼ F-18-ﬂuorodeoxyglucose;














Figure 3. The path to the histologic proof of sarcoidosis. In 60 patients with
unknown histology at presentation, 101 tissue samples were taken and
studied histologically in 3 successive biopsy rounds. Totally 24 MLNB and
71 EMBs were done. Granulomatous inﬂammation was ultimately
conﬁrmed in 24 of 24 MLNBs and in 30 of 71 EMBs. “*” Indicates “other”
biopsy sites that included 2 transbronchial lung biopsies, 2 inguinal lymph
node biopsies, and 1 post-transplantation study of the native
heart; þ/n ¼ number of patients with positive biopsies per number of
patients biopsied. MLNB ¼ mediastinal lymph node biopsies.
Cardiomyopathy/Diagnosis of Cardiac Sarcoidosis 1583heart failure (n ¼ 7, 10%), ventricular ﬁbrillation (n ¼ 4,
6%), and multiple ventricular premature beats (n ¼ 2, 3%).
An impaired LV function at echocardiography on admission
(ejection fraction <50%) was found in 33 patients (49%),
and Gd-MRI revealed pathologic LV wall late enhancement
in 33 of the 43 patients studied (77%). Cardiac PET was
abnormal in 62 of 68 patients. It showed both an F-18-FDG
“hot spot” and a myocardial perfusion defect in 52 patients
and either a perfusion defect or a “hot spot” in 10 patients.
Of the 6 patients with normal cardiac F-18-FDG PET, 5 had
pathologic late enhancement at Gd-MRI.
Cardiac and whole-body PET combined showed patho-
logically increased F-18-FDG uptake (Figure 2) in MLN
in totally 43 of the 68 CS patients (63%). Most of the
PET-positive lymph nodes were located in the right upper
and lower paratracheal regions, subcarinally and in the
subaortic and para-aortic areas. Their number ranged from
2 to 14 per patient (mean 4), and their size averaged 1.2 
0.3 cm. Table 1 gives a complete list of sites of pathologic
extracardiac F-18-FDG uptake in the 57 patients whounderwent whole-body PET imaging. The data show that
although 18 of 57 patients (32%) had F-18-FDG accumu-
lation outside mediastinum, all except 1 of them also had
parallel MLN involvement. None of the 6 patients with
normal cardiac PET had abnormal extracardiac F-18-FDG
activity, indicating that these 6 studies (9% of all) were
completely false negative.
1584 The American Journal of Cardiology (www.ajconline.org)Figure 3 summarizes the path of successive biopsies to
the ultimate histologic diagnosis in the 60 patients with
missing histology of sarcoidosis at presentation. Biopsy of
MLN via mediastinoscopy was done as the ﬁrst procedure in
4 patients and after failing EMBs in 20 patients. It conﬁrmed
sarcoidosis histology in 24 of 24 attempts (sensitivity
100%). Fifty-six patients underwent solitary or repeated
EMBs (totally 71) that ultimately proved the histology of
sarcoidosis in 30 patients (cumulative sensitivity 54%). In
the remaining 6 patients, biopsy of lung or peripheral lymph
nodes conﬁrmed sarcoidosis in 4 patients and the histologic
diagnosis was made only after transplantation or at autopsy
in 2 patients. One of the 24 patients who underwent
mediastinoscopy had transient hoarseness of voice but no
serious complications occurred. After 71 EMBs, 1 patient
had a small amount of pericardial effusion that resolved
spontaneously and 1 other patient showed mild new
tricuspid regurgitation.
Discussion
The key ﬁnding of our observational series was that, in
CS, MLN show abnormal F-18-FDG uptake at PET in most
patients and that their sampling provides a highly productive
means to prove the histology of sarcoidosis. Otherwise, our
work showed that the sensitivity of EMB in CS is better than
previously reported and can exceed 50% if the procedure is
guided by ﬁndings at cardiac imaging and repeated if
initially negative. This is noteworthy because, as our whole-
body PET studies indicated (see Table 1), sarcoidosis is
truly isolated to the heart in 1/3 of CS and cannot be
histologically conﬁrmed without microscopy of myocardial
samples.
Diagnosis of CS has important prognostic and thera-
peutic implications to the individual involved. It nearly
invariably sets off long-term immunosuppressive treatment
and also constitutes an indication to consider a prophylactic
intracardiac cardioverter deﬁbrillator.6 Therefore, and given
the potential complications of these treatments, the diag-
nosis should leave no room for doubt. An absolute diagnosis
of CS only comes from a sample of myocardium showing
typical noncaseating granulomatous histology in the absence
of other explanations. Histologically proved extracardiac
sarcoidosis combined with ﬁndings at cardiac imaging
indicative of nonischemic myocardial involvement consti-
tutes a less certain yet clinically sufﬁcient diagnosis of CS.6
Although diagnosing CS without any histologic proof has
been possible,14 this policy was plainly dismissed in the
recent expert consensus statement from the Heart Rhythm
Society.6 The consensus report6 preferred extracardiac tissue
biopsies over EMB in suspected CS with arguments of
safety and yield. In our practice, EMB has hitherto been the
primary procedure for histologic diagnosis. Worthy of note,
we have shown both here and previously5 that targeting
endomyocardial sampling, with the help of modern cardiac
imaging, combined with willingness to repeat the procedure,
signiﬁcantly increases the yield from EMB. Electroanatomic
mapping-guided myocardial sampling provides another
means to improve the sensitivity of EMB.15
MLN “hot” (i.e., avid for F-18-FDG) at PET served here
as a perfect target for extracardiac biopsies to conﬁrm thehistology of sarcoidosis after nonrevealing EMB. Because
2/3 of our patients in need of histologic diagnosis had “hot”
mediastinum at PET, starting with mediastinoscopy instead
of EMB had certainly simpliﬁed and shortened the diag-
nostic path to a considerable extent (see Figure 3). In this
light, our results clearly support the new consensus state-
ment favoring extracardiac biopsies over EMB.6 In contrast,
EMB is still needed to conﬁrm the diagnosis of isolated
CS and it also enables other than histologic studies,
like myocardial gene expression proﬁling, that may help
detect CS.16
Abnormal extracardiac uptake of F-18-FDG at PET was
observed much more commonly in the mediastinum than in
all other extracardiac sites together (63% vs 26%). Teirstein
et al17 also found in their whole-body PET studies that MLN
constitute by far the most common site of hidden extrac-
ardiac disease in sarcoidosis. Lymphatic drainage from the
left side of the heart is collected in the right upper para-
tracheal nodes18 that could explain why granulomatous
inﬂammation in CS frequently involves the mediastinal
nodes but spares the hilar nodes.5,19 Although MLN provide
a yielding biopsy target in suspected CS, other causes of
noncaseating granulomatous lymphadenitis must always be
excluded, and as Thachil et al20 have shown, particularly,
cautious interpretation is needed in areas endemic for
tuberculosis.
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